Guardant Health stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 85.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Decades of market research shows that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Is Guardant Health Stock A Buy?
While Guardant Health stock is not near an ideal buying range right now, see if it is able to form and break out from a proper chart pattern. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The medical service provider reported 0% earnings growth last quarter, while sales growth came in at 26%.
Guardant Health stock holds the No. 14 rank among its peers in the Medical-Services industry group. InfuSystems Holdings and Option Care Health are also among the group's highest-rated stocks.
